For research and educational purposes only. Not medical advice.
Exenatide Reference
Educational, not medical advice reference for Exenatide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes…
Reference summary
Exenatide was the first GLP-1 receptor agonist approved in the US and is one of the longest-running safety-evidence GLP-1s. pepSmart surfaces label-reference schedules only.
Regulatory and posture
- Categories
- GLP-1, Fat Loss
- Aliases
- Byetta, Bydureon BCise, Exendin-4 analog
- Evidence posture
- human
- Regulatory status
- FDA-approved exenatide label references exist for Byetta (twice-daily, first approved 2005) and Bydureon BCise (once-weekly extended-release). Both are approved as adjuncts to diet and exercise in adults with type 2 diabetes; they are not approved as weight-loss therapies.
- Content review status
- label verified
Selected public sources
Related tools
- GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
- GLP-1 ramp planner - Preview a linear educational dose-step table.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
- GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.
- Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.